No, as of September 2026 there is no veterinary CBD-based medicine authorized in France, for dogs or for any other species. CBD isn't authorized either as an additive or raw material in animal feed. A vet can raise the subject with you and, in some cases, prescribe an off-label product under their own responsibility, but they cannot prescribe any validated CBD medicine, since none exists for this species.
This regulatory gap doesn't rule out veterinary research on the subject, with real but limited preliminary results. This guide reviews the legal status, what the available studies actually show, and a far better documented risk: THC in dogs.
WorldWeed doesn't sell any product intended for animals. This text is general information, not an invitation to give your dog anything without first talking to a vet.
Key points — No veterinary CBD medicine is authorized in France as of September 2026, and CBD isn't authorized in animal feed. Two preliminary trials (Gamble et al. 2018 on osteoarthritis, McGrath et al. 2019 on epilepsy) report encouraging results in small samples of dogs, without amounting to definitive proof or authorization. THC, on the other hand, is well documented as toxic to dogs: lethargy, loss of balance, possible vomiting. Only a vet can assess whether this approach is appropriate on a case-by-case basis.
The status of CBD for dogs in France and the EU
Two separate frameworks govern the situation. On one side, veterinary medicine status: a product that claims a therapeutic effect in dogs - managing pain, reducing seizures, calming anxiety - is by definition a veterinary medicine, and must obtain a market authorization issued by the French National Agency for Veterinary Medicinal Products (ANMV) or by the European Commission, based on a quality, safety and efficacy file. No CBD product has cleared this step to date for any animal species.
On the other side, food status: a supplement or treat for dogs containing CBD falls under the animal feed framework, where CBD isn't authorized as an additive or raw material. The Directorate General for Food (DGAL) stepped up its checks on this type of product in 2026, in line with the same movement targeting CBD food products for humans. In practice, a CBD product for dogs sold in France today therefore has neither validated medicine status nor compliant food-supplement status - a point to check yourself before any purchase, as the situation may change.
Dogs have, like humans, an endocannabinoid system with CB1 and CB2 receptors - this shared physiological feature is what prompted the first veterinary research. On its own it says nothing about the safety or effectiveness of a given product: only the controlled studies presented below allow for cautious progress on this front.
What veterinary studies show - preliminary research
Osteoarthritis: the Cornell study (Gamble et al., 2018)
Published in Frontiers in Veterinary Science, this study first established CBD's pharmacokinetic profile in dogs, then tested a double-blind, placebo-controlled protocol on a small group of dogs with osteoarthritis, over four weeks. The authors report improved pain and activity scores in dogs receiving CBD compared with placebo. This is a pilot study, with a small sample and a short duration: it opens a lead, it doesn't constitute sufficient proof for a validated indication.
Drug-resistant epilepsy: the Colorado State study (McGrath et al., 2019)
Published in the Journal of the American Veterinary Medical Association, this randomized study compared CBD added to a standard antiepileptic treatment against a placebo, in dogs with idiopathic epilepsy resistant to existing treatments, over twelve weeks. A majority of dogs in the CBD group saw their seizure frequency decrease, with a statistical association between blood CBD concentration and the extent of this reduction. Here too, the sample remains small, and the study replaces neither veterinary advice nor an existing antiepileptic treatment.
The limits of this data
These two trials share common limitations: a low number of dogs (around fifteen to twenty per study), a duration of a few weeks to a few months, and the absence of long-term data on large, diverse populations. Neither has served as the basis for a veterinary medicine authorization. More recent work, such as a long-term tolerability study published in 2024 (Corsato Alvarenga et al., Journal of Veterinary Internal Medicine), is starting to document the tolerability of prolonged supplementation in healthy dogs, but the path to a robust, large-scale efficacy assessment remains long.
THC toxicity in dogs, a well-documented risk
Unlike CBD, THC toxicity in dogs is solidly established in the veterinary literature, notably via the Merck Veterinary Manual. Dogs are particularly sensitive to it: marked lethargy, loss of balance (ataxia), vomiting, hypersensitivity to stimuli, tremors and urinary incontinence are among the reported signs. Symptoms generally appear within an hour of ingestion and can persist for up to 72 hours; the outcome is most often favourable, but significant ingestion always warrants prompt veterinary advice. This is one of the reasons only products under 0.3% THC are authorized for sale to humans in France - a threshold never designed for use in dogs, and one no product should exceed, even more so for a dog.
Possible drug interactions
In humans, CBD slows the activity of several liver enzymes that metabolize many common medicines - a mechanism detailed in our article on CBD side effects and safety profile. The available veterinary studies, notably Gamble et al., recommend similar caution in dogs, particularly for ongoing antiepileptic treatments, anticoagulants or immunosuppressants. This is a further reason why a dog on chronic treatment shouldn't be given any CBD product without first talking to their vet.
The vet's role: what they can and can't do
A vet can assess the dog's general health, current treatments, and discuss whether an approach is appropriate case by case. In certain situations, they can use the therapeutic cascade - the option of using, under their own responsibility, a product without a market authorization for this specific indication, in the absence of a validated alternative. What they can't do is prescribe an authorized CBD medicine for dogs: this medicine simply doesn't exist in France as of September 2026. Any claim of effectiveness shown on a product sold without veterinary oversight should be treated with the same caution as for a human product.
Common mistakes and dangers to avoid
- Giving a CBD product designed for humans, which may contain xylitol, chocolate or flavourings toxic to dogs.
- Giving a product labelled full spectrum with no certainty about its actual THC content, without a verifiable COA for the batch concerned.
- Stopping or changing a prescribed antiepileptic or anti-inflammatory treatment without the treating vet's advice.
- Treating an encouraging result from around fifteen dogs as valid proof for every case.
- Ignoring signs suggesting THC poisoning while waiting for them to pass on their own.
WorldWeed sells flowers and CBD resins intended for human use, not products for animals: none of these items are suited to a dog, whether by route of administration (inhalation), concentration, or the possible presence of compounds that are unnecessary or risky for this species.
Sources
- Gamble L.J., Boesch J.M., Frye C.W. et al., « Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs », Frontiers in Veterinary Science, 2018.
- McGrath S., Bartner L.R., Rao S. et al., « Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy », Journal of the American Veterinary Medical Association, 2019.
- Corsato Alvarenga I. et al., « Tolerability of long-term cannabidiol supplementation to healthy adult dogs », Journal of Veterinary Internal Medicine, 2024.
- Merck Veterinary Manual, « Toxicosis in Dogs and Cats From Tetrahydrocannabinol (THC) », toxicology section.
- Ministère de l'Agriculture, de la Souveraineté alimentaire et de la Forêt, notice « Denrées alimentaires contenant du cannabidiol (CBD) : des produits illégaux qui doivent être retirés du marché », 20 May 2026.
